Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22999867 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL4510205 | 1.00 | — | — | |
| SCHEMBL1360201 | 0.97 | — | — | |
| SCHEMBL10261945 | 0.97 | — | — | |
| SCHEMBL10261526 | 0.97 | — | — | |
| Acetic Acid SCHEMBL15769363 | 0.87 | CRBN (0.33) | — | |
| Acetic Acid SCHEMBL431606 | 0.87 | CRBN (0.33) | — | |
| Acetic Acid SCHEMBL15769581 | 0.87 | CRBN (0.33) | — | |
| Hydrochloric Acid SCHEMBL26675905 | 0.86 | TRIM24 (0.33) | — | |
| SCHEMBL6582866 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179079-A1 | HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250163021-A1 | 2-METHYL-4-PHENYLPIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2025-05-22 | — | — | US | disclosed |
| US-20250136620-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4496796-A1 | HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS | Ventus Therapeutics U.S., Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| EP-4476199-A1 | 2-METHYL-4-PHENYLPIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-118984821-A | 2-Methyl-4-phenylpiperidin-4-ol derivatives as APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2024-11-19 | — | — | CN | disclosed |
| WO-2023183275-A1 | HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS | VENTUS THERAPEUTICS U.S., INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023154310-A1 | 2-METHYL-4-PHENYLPIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023137225-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-10246462-B2 | Chemokine receptor modulators and uses thereof | FLX BIO, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| WO-2018049271-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | FLX BIO, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2018-03-15 | — | — | US | disclosed |
| US-8809352-B2 | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| EP-2475661-B1 | SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| CN-102498111-A | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer | NOVARTIS AG | 2012-06-13 | — | — | CN | disclosed |